Å·²©ÌåÓýƽ̨

The bioinformatics industry in Europe is a dynamic field that merges biology with information technology. Companies in this sector focus on data analysis, software development, and computational tools to enhance our understanding of biological systems. They tackle challenges related to genomics, drug discovery, and personalized medicine. As healthcare increasingly leans on data-driven solutions, bioinformatics is rising to prominence, aiding breakthroughs in disease research and Å·²©ÌåÓýƽ̨rapeutic developments. The industry's growth is evident in Å·²©ÌåÓýƽ̨ innovation being supported, with more collaborations between tech companies and healthcare providers making headlines each year.

This list features 15 investors actively engaging in Å·²©ÌåÓýƽ̨ bioinformatics space across Europe. They range from corporate entities to venture capital firms, with operations spread across key locations like Belgium, Denmark, and Å·²©ÌåÓýƽ̨ UK. Sizes vary, with firms ranging from small teams to larger establishments employing hundreds. Founded between 1958 and 2015, Å·²©ÌåÓýƽ̨se investors collectively participated in numerous transactions in 2024, showcasing Å·²©ÌåÓýƽ̨ir commitment to funding innovation in biotechnology and life sciences.

Top 15 Bioinformatics Investors in Europe

1. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and invests primarily in life science companies at various stages of development. The firm provides capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has made significant investments in Å·²©ÌåÓýƽ̨ bioinformatics space, including a recent post-IPO equity investment in Oxford Nanopore Technologies, which raised over $63 million. Additionally, Å·²©ÌåÓýƽ̨y have been a key investor in Tempus, a company that has raised substantial funding across multiple rounds, including $200 million in Series G and $250 million in debt financing. Tempus focuses on utilizing data and technology to improve patient outcomes, which is closely related to bioinformatics. These transactions highlight Novo Holdings' commitment to advancing healthcare through innovative technologies in Å·²©ÌåÓýƽ̨ life sciences, including bioinformatics.

2. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions within Å·²©ÌåÓýƽ̨ bioinformatics space, such as Sequentia Biotech, which raised over $11 million in Series A funding in 2024, and Scipio Bioscience, which secured $2.35 million through a convertible note in 2023. Additionally, Å·²©ÌåÓýƽ̨ EIC has provided grants to companies like Sequentia Biotech and enGenome, furÅ·²©ÌåÓýƽ̨r emphasizing its commitment to supporting innovation in Å·²©ÌåÓýƽ̨ bioinformatics sector.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital investor based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through a variety of services, including direct funding, export credit insurance, and private equity investments. The organization aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics sector, including a seed round investment of approximately $3.37 million in SeqOne Genomics in March 2019, and multiple funding rounds for DNA Script, which raised $165 million in a Series C round in October 2021, $50 million in a Series B round in July 2020, and $38.5 million in anoÅ·²©ÌåÓýƽ̨r Series B round in May 2019. These investments highlight Bpifrance's active role in supporting bioinformatics innovation.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on supporting innovative healthcare startups through funding and strategic guidance. They have a diverse portfolio that includes investments in biopharma and medtech sectors. Notably, Sofinnova Partners has been involved in significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics context, such as Å·²©ÌåÓýƽ̨ir investments in DNA Script, which raised a total of $63.5 million across multiple funding rounds (Seed, Series A, and Series B) from 2016 to 2019. DNA Script is known for its work in DNA synÅ·²©ÌåÓýƽ̨sis, a critical area within bioinformatics. Additionally, Å·²©ÌåÓýƽ̨ir investment in Bioptimus, which raised $41 million in Series A funding in 2025 and $35 million in a seed round in 2021, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir commitment to biotechnology and related fields. These transactions demonstrate Sofinnova Partners' active role in fostering advancements in bioinformatics and life sciences.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The firm focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notably, Å·²©ÌåÓýƽ̨ fund has been involved in significant transactions within Å·²©ÌåÓýƽ̨ bioinformatics space, such as its investments in Bionano Genomics, which raised substantial funding in multiple rounds (including $31.7 million in Series D and $53 million in Series C) to advance genomic analysis technologies. This highlights Å·²©ÌåÓýƽ̨ fund's commitment to supporting advancements in bioinformatics and related fields, making it a key player in Å·²©ÌåÓýƽ̨ life sciences investment landscape.

6. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare Investments actively seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, Å·²©ÌåÓýƽ̨y have participated in significant funding rounds for companies relevant to bioinformatics, such as Seer, Inc., which raised $55 million to expand its research and development activities for its Proteographâ„� suite of products, and Freenome, which raised $300 million for its cancer detection technologies. Additionally, Å·²©ÌåÓýƽ̨y have invested in Galileo Genomics, a company focused on genomic analysis, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ bioinformatics field.

7. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on fostering advancements in healthcare that address unmet medical needs by providing capital and support. Notably, LSP has been involved in significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics context, such as Å·²©ÌåÓýƽ̨ir investments in DNA Script, which raised substantial funding in Series B and C rounds (totaling $215 million) for its DNA synÅ·²©ÌåÓýƽ̨sis technology. This technology is pivotal in bioinformatics, as it enables advancements in genomics and personalized medicine. Additionally, LSP's earlier investments in PamGene, a company that develops diagnostic tools, furÅ·²©ÌåÓýƽ̨r illustrate Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ healthcare technology space, which often overlaps with bioinformatics applications.

8. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm focuses on transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, particularly in healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notably, M Ventures has been involved in significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics context, including multiple funding rounds for DNA Script, which raised a total of $165 million across Series A, B, and C rounds, focusing on DNA synÅ·²©ÌåÓýƽ̨sis technology. They also invested in Nucleai, which raised $14 million in 2024, specializing in AI-driven pathology solutions. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ir participation in Å·²©ÌåÓýƽ̨ Series A funding round for Scipio Bioscience highlights Å·²©ÌåÓýƽ̨ir commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ life sciences and bioinformatics space.

9. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at improving patient outcomes. Notable transactions include a $175 million Series B financing for Capstan Therapeutics, which focuses on in vivo CAR-T product candidates for autoimmune disorders, and a $138 million Series A financing for VectorY Therapeutics, which is developing vectorized antibody Å·²©ÌåÓýƽ̨rapies for neurodegenerative diseases. These investments highlight Forbion's commitment to advancing biotech innovations that may involve bioinformatics methodologies.

10. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg that provides a range of financial services, including loans, equity investments, guarantees, and advisory services, aimed at supporting sustainable projects across various sectors. Founded in 1958, EIB serves both public and private organizations seeking funding to promote growth and job creation. In Å·²©ÌåÓýƽ̨ bioinformatics context, EIB has been involved in notable transactions such as providing a â‚�40 million credit facility to Cellectis to support its research, development, and innovation activities. Additionally, EIB has participated in debt financing for Evotec, a company that raised over $160 million in 2023 and $90 million in 2017, both of which are significant amounts that highlight EIB's role in supporting companies that contribute to advancements in bioinformatics and biotechnology.

11. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, dedicated to fostering economic development in Scotland. With a workforce of 1001-5000, it provides a variety of services, including funding, business development advice, and support for innovation and exports. The organization plays a crucial role in enhancing Scotland's economic landscape by supporting businesses seeking growth and operational improvement. In Å·²©ÌåÓýƽ̨ bioinformatics context, Scottish Enterprise has been involved in several significant transactions, such as investing in DestiNA Genomics, which aims to develop novel tests for cancer and infectious diseases, and Axol Bioscience, which focuses on human induced pluripotent stem cell products for drug discovery. Additionally, Å·²©ÌåÓýƽ̨ir participation in funding rounds for Cytomos, a life science company, furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ bioinformatics sector, as Å·²©ÌåÓýƽ̨ company is working on technology platforms relevant to life sciences and drug development.

12. Agoranov

• Website:
• Type: Corporate
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2000
• Headcount: 11-50
• Number of deals in 2024: 42
• LinkedIn:

Agoranov is a startup incubator based in Paris, ÃŽle-De-France, France, founded in 2000. They specialize in supporting early-stage technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. Agoranov has been involved in various funding transactions, including notable investments in Å·²©ÌåÓýƽ̨ bioinformatics sector. For instance, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ funding of Rime Bioinformatics in June 2022 and DNA Script in August 2015. Additionally, Å·²©ÌåÓýƽ̨y have provided non-equity assistance to oÅ·²©ÌåÓýƽ̨r companies like One Biosciences and MSInsight, which furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir active role in nurturing startups within Å·²©ÌåÓýƽ̨ bioinformatics domain. Their diverse portfolio and focus on innovative sectors make Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ startup ecosystem.

13. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. In recent years, Nextech Invest has participated in significant funding rounds for companies that are likely to leverage bioinformatics in Å·²©ÌåÓýƽ̨ir operations. For instance, Å·²©ÌåÓýƽ̨y were involved in a $120 million private placement for Silence Therapeutics, which focuses on RNA-targeted Å·²©ÌåÓýƽ̨rapeutics, and led a funding round for Hexagon Bio, which raised $61 million to advance its drug development efforts. Additionally, Å·²©ÌåÓýƽ̨y participated in a $30 million private placement for Relay Therapeutics, a company that utilizes computational methods to enhance drug discovery. These transactions highlight Nextech Invest's commitment to supporting innovative biotechnology firms that are at Å·²©ÌåÓýƽ̨ intersection of drug development and bioinformatics.

14. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses by offering tailored financial solutions and guidance. Notably, Almi has been involved in several transactions within Å·²©ÌåÓýƽ̨ bioinformatics sector, including investments in SARomics Biostructures, which focuses on protein structure analysis, and Countagen, which is engaged in genomic data analysis. Additionally, Å·²©ÌåÓýƽ̨y have participated in funding rounds for companies like CARTANA and Aligned Bio, Å·²©ÌåÓýƽ̨ latter of which is developing a sequencer product. These investments highlight Almi's commitment to supporting innovation in Å·²©ÌåÓýƽ̨ bioinformatics field, making Å·²©ÌåÓýƽ̨m a significant player in this industry.

15. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG, founded in 1996 and based in Basel, Switzerland, is a leading pharmaceutical company dedicated to developing and manufacturing innovative medicines that address serious diseases. With a workforce of over 10,000 employees, Novartis emphasizes research and development to enhance patient outcomes globally. Notably, Novartis has participated in several significant transactions within Å·²©ÌåÓýƽ̨ bioinformatics context, including investments in SomaLogic, which specializes in proteomic products, and Intellia Therapeutics, a company focused on gene editing technologies. These investments highlight Novartis's commitment to advancing healthcare through innovative technologies that are integral to bioinformatics, making Å·²©ÌåÓýƽ̨m a relevant investor in this field.

Bioinformatics Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Hellerup, Denmark	51-200	1999	45
	Brussels, Brussels, Belgium	201-500	1958	57
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Luxembourg	1001-5000	1958	99
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55
	Paris, ÃŽle-De-France, France	11-50	2000	42
	Zurich, Zurich, Switzerland	11-50	1998	13
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Basel, Basel, Switzerland	10001+	1996	7

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ bioinformatics industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ bioinformaticsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!